Nanoinformatics: A new area of research in nanomedicine

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 3867-3890

  Maojo, Victor ^a   Fritts, Martin ^b,c   de la Iglesia, Diana ^a   Cachau, Raul E ^b   Garcia Remesal, Miguel ^a   Mitchell, Joyce A ^d   Kulikowski, Casimir ^e  

^a UNIVERSIDAD POLITÉCNICA DE MADRID   (Spain)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL INSTITUTE OF STANDARDS AND TECHNOLOGY   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e RUTGERS UNIVERSITY   (United States)

Author keywords

Biomedical informatics; Electronic health records; Nanomedicine; Nanotoxicology; Ontologies

Indexed keywords

NANOMATERIAL; QUANTUM DOT;

ADVERSE OUTCOME; BIOINFORMATICS; HUMAN; LIPOSOMAL GENE DELIVERY SYSTEM; MOLECULAR MODEL; NANOANALYSIS; NANOCATALYST; NANOCHEMISTRY; NANODEVICE; NANOINFORMATICS; NANOMEDICINE; NOMENCLATURE; PARTICLE SIZE; QUANTUM CHEMISTRY; QUANTUM MECHANICS; REVIEW; TOXICITY TESTING; TRANSLATIONAL RESEARCH;

BIOMEDICAL RESEARCH; ELECTRONIC HEALTH RECORDS; HUMANS; MEDICAL INFORMATICS; NANOMEDICINE;

EID: 84870312354     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S24582     Document Type: Review

References (125)

1. Blum BI, Duncan K, eds. A History of Medical Informatics. New York, NY: ACM Press; Reading, MA: Addison-Wesley; 1990.
2. Ledley RS, Lusted LB. Reasoning foundations of medical diagnosis; symbolic logic, probability, and value theory aid our understanding of how physicians reason. Science. 1959;130(3366):9-21.
3. Kay L. Who Wrote the Book of Life? A History of the Genetic Code. Palo Alto, CA: Stanford University Press; 2000.
4. Collins FS, Morgan M, Patrinos A. The Human Genome Project: lessons from large-scale biology. Science. 2003;300(5617):286-290.
5. Gene Ontology Consortium. Creating the gene ontology resource: design and implementation. Genome Res. 2001;11(8):1425-1433.
6. Kulikowski CA. The micro-macro spectrum of medical informatics challenges: from molecular medicine to transforming health care in a globalizing society. Methods Inf Med. 2002;41(1):20-24.
7. Kohane IS. Bioinformatics and clinical informatics: the imperative to collaborate. J Am Med Inform Assoc. 2000;7(5):512-516.
8. Maojo V, Kulikowski CA. Bioinformatics and medical informatics: collaborations on the road to genomic medicine? J Am Med Inform Assoc. 2003;10(6):515-522.
9. Galperin MY, Fernández-Suárez XM. The 2012 Nucleic Acids Research Database Issue and the online Molecular Biology Database Collection. Nucleic Acids Res. 2012;40(Database issue):D1-D8.
10. Brooksbank C, Cameron G, Thornton J. The European Bioinformatics Institute's data resources. Nucleic Acids Res. 2010;38(Database issue): D17-D25.
11. Wu C, Orozco C, Boyer J, et aI. BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. Genome Biol. 2009;10(11):R130.
12. Flicek P, Amode MR, Barrell D, etal. Ensembl 2012. Nucleic Acids Res. 2012;40(Database issue):D84-D90.
13. Maglott D, Ostell J, Pruitt KD, Tatusova T. Entrez Gene: gene-centered information at NCBI. Nucleic Acids Res. 2011;39(Database issue): D52-D57.
14. Li Z, Liu X, Wen J, etal. DRUMS: a human disease related unique gene mutation search engine. Hum Mutat. 2011;32(10):E2259-E2265.
15. Schriml LM, Arze C, Nadendla S, etal. Disease Ontology: a backbone for disease semantic integration. Nucleic Acids Res. 2012;40(Database issue):D940-D946.
16. Jonquet C, Shah NH, Musen MA. The open biomedical annotator. Summit on Translat Bioinforma. 2009;2009:56-60.
17. Courtot M, Juty N, Knüpfer C, etal. Controlled vocabularies and semantics in systems biology. Mol Syst Biol. 2011;7:543.
18. Schofield PN, Hancock JM. Integration of global resources for human genetic variation and disease. Hum Mutat. 2012;33(5):813-816.
19. Kim BY, Rutka JT, Chan WC. Nanomedicine. N Engl J Med. 2010;363(25):2434-2443.
20. Freitas RA Jr. Nanomedicine, Volume I: Basic Capabilities. Georgetown, TX: Landes Bioscience; 1999. Available from: http://www.nanomedicine.com/NMI.htm. Accessed February 28, 2012.
21. Jain KK. A Handbook of Nanomedicine. Totowa, NJ: Humana/Springer; 2008.
22. Liu C, Zhang N. Nanoparticles in gene therapy principles, prospects, and challenges. Prog Mol Biol Transl Sci. 2011;104:509-562.
23. Bellare JR. Nanotechnology and nanomedicine for healthcare: challenges in translating innovations from bench to bedside. J Biomed Nanotechnol. 2011;7(1):36-37.
24. Maojo V, Martin-Sanchez F, Kulikowski C, Rodriguez-Paton A, Fritts M. Nanoinformatics and DNA-based computing: catalyzing nanomedicine. Pediatr Res. 2010;67(5):481-489.
25. Workshop on Nanoinformatics Strategies. 2007 June 12-13, Arlington, VA, USA. National Science Foundation-National Nanomanufacturing Network; nd. Available from: http://semanticommunity.info/@api/deki/files/1347/=Purpose.pdf. Accessed February 28, 2012.
26. Lymberis A. Converging micro-nano-bio technologies towards integrated biomedical systems: state of the art and future perspectives under the EU-information and communication technologies program. Conf Proc IEEE Eng Med Biol Soc. 2008;2008:6-8.
27. Stone AJ, editor. The Theory of Intermolecular Forces. Oxford University Press; Oxford, England. 1996.
28. Zhou C, Yu J, Qin Y, Zheng J. Grain size effects in polycrystalline gold nanoparticles. Nanoscale. 2012. (Epub ahead of print).
29. Oezaslan M, Heggen M, Strasser P. Size-dependent morphology of dealloyed bimetallic catalysts: linking the nano to the macro scale. J Am Chem Soc. 2012;134(1):514-524.
30. Teli MK, Mutalik S, Rajanikant GK. Nanotechnology and nanomedicine: going small means aiming big. Curr Pharm Des. 2010; 16(16):1882-1892.
31. Ma X, Zhao Y, Liang XJ. Theranostic nanoparticles engineered for clinic and pharmaceutics. Acc Chem Res. 2011;44(10):1114-1122.
32. Youns M, Hoheisel JD, Efferth T. Therapeutic and diagnostic applications of nanoparticles. Curr Drug Targets. 2011;12(3):357-365.
33. Bharali DJ, Khalil M, Gurbuz M, Simone TM, Mousa SA. Nanoparticles and cancer therapy: a concise review with emphasis on dendrimers. Int J Nanomedicine. 2009;4:1-7.
34. Harper S, Usenko C, Hutchison JE, Maddux BL, Tanguay RL. In vivo biodistribution and toxicity depends on nanomaterial composition, size, surface functionalisation and route of exposure. J Exp Nanosci. 2008;3(3):195-206.
35. Ruggiero C, Pastorino L, Herrera OL. Nanotechnology based targeted drug delivery. Conf Proc IEEE Eng Med Biol Soc. 2010;2010:3731-3732.
36. Graham LM, Nguyen TM, Lee SB. Nanodetoxification: emerging role of nanomaterials in drug intoxication treatment. Nanomedicine (Lond). 2011;6(5):921-928.
37. Phan JH, Moffitt RA, Stokes TH, etal. Convergence of biomarkers, bioinformatics and nanotechnology for individualized cancer treatment. Trends Biotechnol. 2009;27(6):350-358.
38. Liu Y, Miyoshi H, Nakamura M. Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int J Cancer. 2007;120(12): 2527-2537.
39. Ptak K, Farrell D, Panaro NJ, Grodzinski P, Barker AD. The NCI Alliance for Nanotechnology in Cancer: achievement and path forward. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010;2(5): 450-460.
40. Vélez JM, Vélez JJ. The eminent need for an academic program in universities to teach nanomedicine. Int J Nanomedicine. 2011; 6:1733-1738.
41. Maojo V, García-Remesal M, de la Iglesia D, etal. Nanoinformatics: developing advanced informatics applications for nanomedicine. In: Prokop A, editor. Intracellular Delivery. Fundamental Biomedical Technologies, 5: Fundamentals and Applications. Dordrecht, Heidelberg, London, New York, NY: Springer; 2011;847-860.
42. Xia XR, Monteiro-Riviere NA, Riviere JE. An index for characterization of nanomaterials in biological systems. Nat Nanotechnol. 2010;5(9):671-675.
43. Dufès C, Uchegbu IF, Schätzlein AG. Dendrimers in gene delivery. Adv Drug Deliv Rev. 2005;57(15):2177-2202.
44. Dobson J. Gene therapy progress and prospects: magnetic nanoparticle-based gene delivery. Gene Ther. 2006;13(4):283-287.
45. De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine. 2008;3(2):133-149.
46. Daum N, Tscheka C, Neumeyer A, Schneider M. Novel approaches for drug delivery systems in nanomedicine: effects of particle design and shape. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2012;4(1):52-65.
47. Wu Z, Chen K, Yildiz I, etal. Development of viral nanoparticles for efficient intracellular delivery. Nanoscale. 2012:4,3567-3576.
48. Herper M. The truly staggering cost of inventing new drugs. Forbes. February 2, 2012. Available from: http://www.forbes.com/sites/matthewherper/2012/02/10/the-truly-staggeringcost-of-inventing-new-drugs/. Accessed April 28, 2012.
49. Iglesias J. nab-Paclitaxel (Abraxane(R): an albumin-bound cytotoxic exploiting natural delivery mechanisms into tumors. Breast Cancer Res. 2009;11 Suppl 1:S21.
50. Luo C, Wang Y, Chen Q, etal. Advances of Paclitaxel formulations based on nanosystem delivery technology. Mini Rev Med Chem. 2012;12(5):434-444.
51. Suri SS, Fenniri H, Singh B. Nanotechnology-based drug delivery systems. J Occup Med Toxicol. 2007;2:16.
52. Phillips MA, Gran ML, Peppas NA. Targeted nanodelivery of drugs and diagnostics. Nano Today. 2010;5(2):143-159.
53. Majoros IJ, Thomas TP, Mehta CB, Baker JR Jr. Poly(amidoamine) dendrimer-based multifunctional engineered nanodevice for cancer therapy. J Med Chem. 2005;48(19):5892-5899.
54. Park JH, von Maltzahn G, Ong LL, etal. Cooperative nanoparticles for tumor detection and photothermally triggered drug delivery. Adv Mater. 2010;22(8):880-885.
55. Huynh L, Neale C, Pomès R, Allen C. Computational approaches to the rational design of nanoemulsions, polymeric micelles, and dendrimers for drug delivery. Nanomedicine. 2012;8(1):20-36.
56. Shaw SY, Westly EC, Pittet MJ, Subramanian A, Schreiber SL, Weissleder R. Perturbational profiling of nanomaterial biologic activity. Proc Natl Acad Sci U S A. 2008;105(21):7387-7392.
57. Elbaz J, Willner I. DNA origami: nanorobots grab cellular control. Nat Mater. 2012;11(4):276-277.
58. Douglas SM, Bachelet I, Church GM. A logic-gated nanorobot for targeted transport of molecular payloads. Science. 2012;335(6070):831-834.
59. Kostarelos K. Nanorobots for medicine: how close are we? Nanomedicine (Lond). 2010;5(3):341-342.
60. Pautler M, Brenner S. Nanomedicine: promises and challenges for the future of public health. Int J Nanomedicine. 2010;5:803-809.
61. Murthy SK. Nanoparticles in modern medicine: state of the art and future challenges. Int J Nanomedicine. 2007;2(2):129-141.
62. Anguita A, Martín L, Crespo J, Tsiknakis M. An ontology-based method to solve query identifier heterogeneity in post-genomic clinical trials. Stud Health Technol Inform. 2008;136:3-8.
63. Barton J, Mathúna SC, O'Reilly S, etal. Micro and nano technology enabling ambient intelligence for P-Health. Stud Health Technol Inform. 2005;117:89-97.
64. Nel AE, Mädler L, Velegol D, etal. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater. 2009;8(7):543-557.
65. Laurencin C, Nair LS. Nanotechnology and Tissue Engineering: The Scaffold. Boca Raton, FL: CRC Press; 2008.
66. Harper SL, Dahl JL, Maddux BL, Tanguay RL, Hutchison JE. Proactively designing nanomaterials to enhance performance and minimize hazard. Int J Nanotechnol. 2008;5(1):124-142.
67. Nyström AM, Fadeel B. Safety assessment of nanomaterials: Implications for nanomedicine. J Control Release. 2012. (Epub ahead of print).
68. Puzyn T, Leszczynska D, Leszczynski J. Toward the development of "nano-QSARs": advances and challenges. Small. 2009;5(22): 2494-2509.
69. Harper SL, Carriere JL, Miller JM, Hutchison JE, Maddux BL, Tanguay RL. Systematic evaluation of nanomaterial toxicity: utility of standardized materials and rapid assays. ACS Nano. 2011;5(6): 4688-4697.
70. Thomas DG, Klaessig F, Harper SL, etal. Informatics and standards for nanomedicine technology. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011. (Epub ahead of print).
71. Ostraat ML. The Nanomaterial Registry [presentation]. Research Triangle Park, NC: RTI International; 2011. Available from: http://www.toxicology.org/isot/ss/nano/docs/Ostraat_guest_presentation.pdf. Accessed April 30, 2012.
72. Kulikowski CA, Kulikowski CW. Biomedical and health informatics in translational medicine. Methods Inf Med. 2009;48(1):4-10.
73. Lavik E, von Recum H. The role of nanomaterials in translational medicine. ACS Nano. 2011;5(5):3419-3424.
74. Kuiken T. Nanomedicine and ethics: is there anything new or unique? Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011;3:111-118.
75. Sandler R. Nanomedicine and nanomedical ethics. Am J Bioeth. 2009;9(10):16-17.
76. Ruping K, Sherman BW. Nanoinformatics: emerging computational tools in nano-scale research. In: Commercial tools, processes and materials, Technical Proceedings of the 2004NSTI Nanotechnology Conference and Trade Show, Volume 3. Austin, TX: Nano Science and Technology Institute; 525-528. Available from: http://www.nsti.org/procs/Nanotech2004v3/11/X33.06. Accessed April 30, 2012.
77. De Rosnay J. From molecular biology to biotics: the development of bio-, info-and nano-technologies. Cell Mol Biol (Noisy-le-grand). 2001;47(8):1261-1268.
78. President's Council of Advisors on Science and Technology. Report to the President and Congress on the Third Assessment of the National Nanotechnology Initiative. Washington DC: Executive Office of the President, President's Council of Advisors on Science and Technology; 2010. Available from: http://www.whitehouse.gov/sites/default/files/microsites/ostp/pcast-nni-report.pdf. Accessed April 30, 2012.
79. De la Iglesia D, Harper S, Hoover MD, et al. Nanoinformatics 2020 Roadmap. Amherst, MA: National Nanomanufacturing Network; 2011. Available from: http://eprints.internano.org/607/1/Roadmap_FINAL041311.pdf. Accessed February 28, 2012.
80. ACTION-Grid Consortium. The ACTION-Grid White Paper: Linking Biomedical Informatics, Grid Computing and Nanomedicine. ACTION-Grid Consortium; 2010. Available from: http://www.action-grid.eu/documents/ACTION-Grid%20White%20Paper.pdf. Accessed February 28, 2012.
81. National Research Council of the National Academies Committee to Develop a Research Strategy for Environmental, Health, and Safety Aspects of Engineered Nanomaterials. A Research Strategy for Environmental, Health, and Safety Aspects of Engineered Nanomaterials. Washington DC: National Academies Press; 2012.
82. Ho D, Garcia D, Ho CM. Nanomanufacturing and characterization modalities for bio-nano-informatics systems. J Nanosci Nanotechnol. 2006;6(4):875-891.
83. Baker NA, Fritts M, Guccione S, etal; National Cancer Institute, caBIG® Integrative Cancer Research Nanotechnology Working Group. Nanotechnology Informatics White Paper. Bethesda, MD: US National Institutes of Health; 2009.
84. Bizer C. The emerging web of linked data. IEEE Intell Syst. 2009; 24(5):87-92.
85. Renear AH, Palmer CL. Strategic reading, ontologies, and the future of scientific publishing. Science. 2009;325(5942):828-832.
86. Spasic I, Ananiadou S, McNaught J, Kumar A. Text mining and ontologies in biomedicine: making sense of raw text. Brief Bioinform. 2005;6(3):239-251.
87. Gordon N, Sagman U. Nanomedicine Taxonomy [briefing paper]. Ottawa: Canadian Institute of Health Research and Canadian NanoBusiness Alliance; 2003.
88. Thomas DG, Pappu RV, Baker NA. NanoParticle Ontology for cancer nanotechnology research. J Biomed Inform. 2011;44(1): 59-74.
89. Alonso-Calvo R, Maojo V, Billhardt H, Martin-Sanchez F, García-Remesal M, Pérez-Rey D. An agent-and ontology-based system for integrating public gene, protein, and disease databases. J Biomed Inform. 2007;40(1):17-29.
90. McCusker JP, Phillips JA, González Beltrán A, Finkelstein A, Krauthammer M. Semantic web data warehousing for caGrid. BMC Bioinformatics. 2009;10 Suppl 10:S2.
91. Stokes TH, Phan J, Quo CF, Nie S, Wang MD. Bio-nano-informatics: an integrated information management system for personalized oncology. Conf Proc IEEE Eng Med Biol Soc. 2006;1: 3325-3328.
92. Papagiannaros A, Levchenko T, Hartner W, Mongayt D, Torchilin V. Quantum dots encapsulated in phospholipid micelles for imaging and quantification of tumors in the near-infrared region. Nanomedicine. 2009;5(2):216-224.
93. Gao X, Yang L, Petros JA, Marshall FF, Simons JW, Nie S. In vivo molecular and cellular imaging with quantum dots. Curr Opin Biotechnol. 2005;16(1):63-72.
94. Baker JR Jr. The need to pursue and publish clinical trials in nanomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011;3(4):341-342.
95. Lanza GM, Yu X, Winter PM, etal. Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis. Circulation. 2002;106(22):2842-2847.
96. Chrastina A, Schnitzer JE. Iodine-125radiolabeling of silver nanoparticles for in vivo SPECT imaging. Int J Nanomedicine. 2010; 5:653-659.
97. Reuveni T, Motiei M, Romman Z, Popovtzer A, Popovtzer R. Targeted gold nanoparticles enable molecular CT imaging of cancer: an in vivo study. Int J Nanomedicine. 2011;6:2859-2864.
98. Sperling RA, Gil PR, Zhang F, Zanella M, Parak WJ. Biological applications of gold nanoparticles. Chem Soc Rev. 2008;37: 1896-1908.
99. Vargas K, Driscoll J. Computational Nanoscience: Applications for Molecules, Clusters, and Solids. Cambridge: Cambridge University Press; 2011.
100. Archakov AI, Ivanov YD. Analytical nanobiotechnology for medicine diagnostics. Mol Biosyst. 2007;3(5):336-342.
101. Bewick S, Yang R, Zhang M. Complex mathematical models of biology at the nanoscale. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009;1(6):650-659.
102. Jaramillo-Botero A, Abrol R, van Duin A, Goddard WA III. Multiscale-multiparadigm modeling and simulation of nanometer scale systems and processes for nanomedical applications. In: Zhang M, Xi N, editors. Nanomedicine: A Systems Engineering Approach. Singapore: Pan Stanford Publishing; 2009:245-300.
103. Chaimovich A, Shell MS. Coarse-graining errors and numerical optimization using a relative entropy framework. J Chem Phys. 2011; 134(9):094112.
104. Cachau RE, Gonzalez-Ibanez AM, Gonzalez-Nilo FD. The collaboratory for structural nanobiology. Nanotech. 2010;3:238-241.
105. de la Calle G, García-Remesal M, Chiesa S, de la Iglesia D, Maojo V. BIRI: a new approach for automatically discovering and indexing available public bioinformatics resources from the literature. BMC Bioinformatics. 2009;10:320.
106. García-Remesal M, Cuevas A, Pérez-Rey D, etal. PubDNA Finder: a web database linking full-text articles to sequences of nucleic acids. Bioinformatics. 2010;26(21):2801-2802.
107. García-Remesal M, Maojo V, Crespo J, Billhardt H. Logical schema acquisition from text-based sources for structured and non-structured biomedical sources integration. AMIA Annu Symp Proc. 2007; 2007:259-263.
108. Ai J, Biazar E, Jafarpour M, etal. Nanotoxicology and nanoparticle safety in biomedical designs. Int J Nanomedicine. 2011;6: 1117-1127.
109. Webster TJ. NanoTox: hysteria or scientific studies? Int J Nanomedicine. 2008;3(2):i-ii.
110. Lai DY. Toward toxicity testing of nanomaterials in the 21st century: a paradigm for moving forward. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2012;4(1):1-15.
111. Adiseshaiah PP, Hall JB, McNeil SE. Nanomaterial standards for efficacy and toxicity assessment. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010;2(1):99-112.
112. Oberdörster G, Oberdörster E, Oberdörster J. Concepts of nanoparticle dose metric and response metric. Environ Health Perspect. 2007; 115(6):A290.
113. Hussain S, Vanoirbeek JA, Hoet PH. Interactions of nanomaterials with the immune system. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2012;4(2):169-183.
114. ISA Commons. What is the ISA framework? In: ISA Commons [homepage on the Internet]. 2011. Available from: http://isacommons.org/. Accessed April 30, 2012.
115. Minimum Information for Nanomaterial Characterization (MINChar) Initiative. Characterization Matters [homepage on the Internet]. 2008. Available from: http://characterizationmatters.org/. Accessed February 28, 2011.
116. Aillon KL, Xie YM, El-Gendy N, Berkland CJ, Forrest ML. Effects of nanomaterial physicochemical properties on in vivo toxicity. Adv Drug Delivery Rev. 2009;61(6):457-466.
117. Peng RD. Reproducible research in computational science. Science. 2011;334(6060):1226-1227.
118. Hasman A, Ammenwerth E, Dickhaus H, etal. Biomedical informatics-a confluence of disciplines? Methods Inf Med. 2011;50(6): 508-524.
119. Kjølberg KL, Strand R. Conversations about responsible nanoresearch. Nanoethics. 2011;5(1):99-113.
120. Sandhiya S, Dkhar SA, Surendiran A. Emerging trends of nanomedicine-an overview. Fundam Clin Pharmacol. 2009;23(3): 263-269.
121. Rosse C, Mejino JL Jr. A reference ontology for biomedical informatics: the Foundational Model of Anatomy. J Biomed Inform. 2003;36(6):478-500.
122. Garten Y, Altman RB. Pharmspresso: a text mining tool for extraction of pharmacogenomics concepts and relationships from full text. BMC Bioinformatics. 2009;10 Suppl 2:S6.
123. Maojo V, Crespo J, García-Remesal M, de la Iglesia D, Perez-Rey D, Kulikowski C. Biomedical ontologies: toward scientific debate. Methods Inf Med. 2011;50(3):203-216.
124. Ito JI, Tabei Y, Shimizu K, Tomii K, Tsuda K. PDB-scale analysis of known and putative ligand-binding sites with structural sketches. Proteins. 2012;80(3):747-763.
125. Riehemann K, Schneider SW, Luger TA, Godin B, Ferrari M, Fuchs H. Nanomedicine-challenge and perspectives. Angew Chem Int Ed Engl. 2009;48(5):872-897.